223 related articles for article (PubMed ID: 32189003)
1. Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study.
Surial B; Ledergerber B; Calmy A; Cavassini M; Günthard HF; Kovari H; Stöckle M; Bernasconi E; Schmid P; Fux CA; Furrer H; Rauch A; Wandeler G;
J Infect Dis; 2020 Jul; 222(4):637-645. PubMed ID: 32189003
[TBL] [Abstract][Full Text] [Related]
2. Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
Surial B; Béguelin C; Chave JP; Stöckle M; Boillat-Blanco N; Doco-Lecompte T; Bernasconi E; Fehr J; Günthard HF; Schmid P; Walti LN; Furrer H; Rauch A; Wandeler G;
J Acquir Immune Defic Syndr; 2020 Oct; 85(2):227-232. PubMed ID: 32925387
[TBL] [Abstract][Full Text] [Related]
3. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
Turner D; Drak D; O'Connor CC; Templeton DJ; Gracey DM
AIDS Res Ther; 2019 Dec; 16(1):40. PubMed ID: 31810490
[TBL] [Abstract][Full Text] [Related]
4. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter?
Vergori A; Gagliardini R; Gianotti N; Gori A; Lichtner M; Saracino A; De Vito A; Cascio A; Di Biagio A; Monforte AD; Antinori A; Cozzi-Lepri A;
Int J Antimicrob Agents; 2020 Dec; 56(6):106154. PubMed ID: 32919008
[TBL] [Abstract][Full Text] [Related]
5. Estimated glomerular filtration rate slopes on tenofovir alafenamide.
Ibrahim F; Campbell L; Bailey AC; Stockwell S; Waters L; Orkin C; Johnson M; Gompels M; De Burgh-Thomas A; Jones R; Schembri G; Mallon PW; Post FA
HIV Med; 2020 Oct; 21(9):607-612. PubMed ID: 33021067
[TBL] [Abstract][Full Text] [Related]
6. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: A retrospective observational study.
Hikasa S; Shimabukuro S; Hideta K; Higasa S; Sawada A; Tokugawa T; Tanaka K; Yanai M; Kimura T
J Infect Chemother; 2022 Mar; 28(3):396-400. PubMed ID: 34896027
[TBL] [Abstract][Full Text] [Related]
7. Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort.
Surial B; Cavassini M; Calmy A; Fehr J; Stöckle M; Bernasconi E; Roth B; Fux CA; Kovari H; Furrer H; Rauch A; Wandeler G;
BMC Infect Dis; 2019 Oct; 19(1):834. PubMed ID: 31601174
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
Sarowar A; Coffin CS; Fung S; Wong A; Doucette K; Truong D; Conway B; Haylock-Jacobs S; Ramji A; Hansen BE; Janssen HLA; Cooper C
J Acquir Immune Defic Syndr; 2022 Dec; 91(4):368-372. PubMed ID: 36288543
[TBL] [Abstract][Full Text] [Related]
9. Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study.
Abe K; Obara T; Kamio S; Kondo A; Imamura J; Goto T; Ito T; Sato H; Takahashi N
AIDS Res Ther; 2021 Dec; 18(1):94. PubMed ID: 34876151
[TBL] [Abstract][Full Text] [Related]
10. eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort.
Teira R; Diaz-Cuervo H; Aragão F; Muñoz J; Galindo P; Merino M; de la Fuente B; Sepúlveda MA; Domingo P; García J; Castaño M; Ribera E; Geijo P; Romero A; Peraire J; Deig E; Roca B; Martínez E; Estrada V; Montero M; Berenguer J; Espinosa N
HIV Res Clin Pract; 2021 Jun; 22(3):78-85. PubMed ID: 34410219
[No Abstract] [Full Text] [Related]
11. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
[TBL] [Abstract][Full Text] [Related]
12. Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.
Campbell L; Barbini B; Burling K; Cromarty B; Hamzah L; Johnson M; Jones R; Samarawickrama A; Williams D; Winston A; Post FA;
J Acquir Immune Defic Syndr; 2021 Oct; 88(2):214-219. PubMed ID: 34506361
[TBL] [Abstract][Full Text] [Related]
13. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back.
Milinkovic A; Berger F; Arenas-Pinto A; Mauss S
AIDS; 2019 Dec; 33(15):2387-2391. PubMed ID: 31764103
[TBL] [Abstract][Full Text] [Related]
14. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
Mills A; Crofoot G; McDonald C; Shalit P; Flamm JA; Gathe J; Scribner A; Shamblaw D; Saag M; Cao H; Martin H; Das M; Thomas A; Liu HC; Yan M; Callebaut C; Custodio J; Cheng A; McCallister S
J Acquir Immune Defic Syndr; 2015 Aug; 69(4):439-45. PubMed ID: 25867913
[TBL] [Abstract][Full Text] [Related]
16. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
Kovari H; Surial B; Tarr PE; Cavassini M; Calmy A; Schmid P; Bernasconi E; Rauch A; Wandeler G; Ledergerber B;
HIV Med; 2021 Aug; 22(7):623-628. PubMed ID: 33880839
[TBL] [Abstract][Full Text] [Related]
17. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting.
Kauppinen KJ; Kivelä P; Sutinen J
AIDS Patient Care STDS; 2019 Dec; 33(12):500-506. PubMed ID: 31742421
[TBL] [Abstract][Full Text] [Related]
18. Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
Hamzah L; Williams D; Bailey AC; Jones R; Ibrahim F; Musso CG; Burling K; Barbini B; Campbell L; Post FA;
HIV Med; 2020 Mar; 21(3):198-203. PubMed ID: 31679186
[TBL] [Abstract][Full Text] [Related]
19. Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.
Hermansson L; Yilmaz A; Price RW; Nilsson S; McCallister S; Makadzange T; Das M; Zetterberg H; Blennow K; Gisslen M
PLoS One; 2019; 14(12):e0226276. PubMed ID: 31826005
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
Kaneko S; Kurosaki M; Tamaki N; Itakura J; Hayashi T; Kirino S; Osawa L; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Yasui Y; Tsuchiya K; Nakanishi H; Takahashi Y; Watanabe M; Izumi N
J Gastroenterol Hepatol; 2019 Nov; 34(11):2004-2010. PubMed ID: 31017689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
